In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner.
InvenSense takes on Johnson & Johnson for this first round-robin match up in our search for the better stock today.
Tech analyst Max Macaluso believes one of the top reasons to be an InvenSense (NYSE:INVN) bull today has to do with the company's tremendous growth potential. This sensor specialist has already benefited from wider adoption of mobile devices and looks poised to also benefit from the growing wearable technology trend. Couple that with its dedication to research and development, and InvenSense can be a market leader over the long term.
Health-care analyst David Williamson believes the No. 1 reason Johnson & Johnson (NYSE:JNJ) should win this match is its diversification. The health-care conglomerate has one of the strongest pharmaceutical divisions in the industry, regularly posting double-digit growth and rolling out exciting drugs like Imbruvica. J&J's medical device unit is still benefiting from the massive $21 billion Synthes acquisition, and its consumer unit has a strong exposure to fast-growing emerging markets. Add in a stable dividend, and investors have a solid defensive stock with nice pharma upside.
Warren Buffett vs. his worst nightmare
Warren Buffett just called this emerging technology a "real threat" to his biggest cash cow. While Buffett shakes in his billionaire boots, only a few investors are embracing this new market, which experts say will be worth over $2 trillion. It won't be long before everyone on Wall Street wises up, and that's why The Motley Fool is releasing this timely investor alert. Click here to learn more about what's keeping Buffett up at night and the one public company we're calling the brains behind the technology.
Vote here to determine the winner of this match, and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson owns shares of Johnson & Johnson. Max Macaluso, Ph.D., has no position in any stocks mentioned. The Motley Fool recommends and owns shares of InvenSense and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.